Our findings indicate that high doses of rosuvastatin impair BCAA catabolism and causes systemic insulin resistance, which is associated with the PP2Cm‐mediated inhibition of Akt and GSK3β signaling pathways. The gene discussed is AKT1; the disease is Insulin resistance.